The Swiss bank believes the pharmaceutical giant's 30-drug-trial pipeline makes it a "leading player in this field" and expects shares to rise by nearly 30%.
from Top News and Analysis (pro) https://ift.tt/1dX6JYA
UBS upgrades Big Pharma stock after shares drop on poor drug results
July 12, 2023
0
